Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates

We conducted a desensitization program in our center in patients undergoing kidney transplant for end-stage renal disease. These patients had a living-donor either ABO incompatible and/or human-leukocyte antigen-incompatible. The safety and efficacy of this program were evaluated. A pretransplant de...

Full description

Saved in:

Bibliographic Details
Published in:	Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation Vol. 13 Suppl 1; p. 165
Main Authors:	Rostaing, Lionel, Maggioni, Sébastien, Hecht, Corinne, Hermelin, Martine, Faudel, Eric, Kamar, Nassim, Sallusto, Federico, Doumerc, Nicolas, Allal, Asma
Format:	Journal Article
Language:	English
Published:	Turkey 01-04-2015
Subjects:	ABO Blood-Group System - immunology Blood Component Removal - adverse effects Blood Component Removal - methods Blood Group Incompatibility - blood Blood Group Incompatibility - diagnosis Blood Group Incompatibility - immunology Blood Group Incompatibility - therapy Desensitization, Immunologic - adverse effects Desensitization, Immunologic - methods Graft Rejection - immunology Graft Rejection - prevention & control Graft Survival Histocompatibility Histocompatibility Testing HLA Antigens - immunology Humans Immunosorbents - adverse effects Immunosorbents - therapeutic use Isoantibodies - blood Kidney Failure, Chronic - blood Kidney Failure, Chronic - diagnosis Kidney Failure, Chronic - immunology Kidney Failure, Chronic - therapy Kidney Transplantation - adverse effects Program Evaluation Renal Dialysis - adverse effects Risk Factors Time Factors Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We conducted a desensitization program in our center in patients undergoing kidney transplant for end-stage renal disease. These patients had a living-donor either ABO incompatible and/or human-leukocyte antigen-incompatible. The safety and efficacy of this program were evaluated. A pretransplant desensitization program relies on immunosuppressants and apheresis to remove detrimental antibodies. We chose immunoadsorption as the apheresis technique, and coupled this with hemodialysis in a tandem procedure. We report on the efficacy of this new method in 120 procedures performed in 20 patients (14 ABO incompatible, 6 ABO incompatible/human leukocyte antigen-incompatible). The tandem procedure was well tolerated, and saved time compared with conducting sequential immunoadsorption and hemodialysis (6 h vs 10 h). The tandem procedure was associated with significantly decreased isoagglutinin titers and donor-specific alloantibodies (assessed by mean fluorescence intensity). Dialysance was effective (183, 102-264). The biochemical and hematologic parameters were similar to those observed after a conventional hemodialysis session, with the exception of protidemia; this might be related to some degree of albumin loss during the immunoadsoprtion procedure. The posttransplant events included 1) one ABO incompatible / human leukocyte antigenincompatible patient with vein thrombosis and ultimate kidney loss; 2) two patients with steroidsensitive cellular acute rejection; and 3) two patients with acute antibody-mediated rejection, which was successfully treated with apheresis and steroid pulses, plus rituximab in one and eculizumab in the other. We conclude that the tandem immunoadsorption-hemodialysis procedure is efficient at desensitizing patients with end-stage renal disease who are candidates for a living ABO incompatible and/or human leukocyte antigenincompatible donor-kidney transplant.
ISSN:	2146-8427
DOI:	10.6002/ect.mesot2014.O146